Adjunctive Dexmedetomidine Therapy in the Intensive Care Unit: A Retrospective Assessment of Impact on Sedative and Analgesic Requirements, Levels of Sedation and Analgesia, and Ventilatory and Hemodynamic Parameters

Feb 24, 2007Pharmacotherapy

Dexmedetomidine added in intensive care: effects on sedation, pain relief, breathing, and heart function

AI simplified

Abstract

In a study involving 40 intensive care patients, 11 of 13 receiving propofol and 14 of 23 receiving lorazepam had their respective sedatives discontinued within 6 hours of starting adjunctive dexmedetomidine therapy.

  • Adjunctive dexmedetomidine was associated with a reduction in the use of propofol but did not significantly alter the use of lorazepam or fentanyl.
  • Adequate sedation levels decreased from 64.6% to 47.9% after the initiation of dexmedetomidine (p=0.001).
  • The incidence of severe agitation increased from 4 patients before to 12 patients after starting dexmedetomidine (p=0.05).
  • The number of patients experiencing severe pain rose from 1 before to 12 after dexmedetomidine was introduced (p=0.02).
  • Nine patients experienced hypotension or bradycardia during the treatment period.
  • Twenty-two patients were successfully extubated within 24 hours of starting dexmedetomidine.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free